Revised hydroxychloroquine PBS listings for the treatment of autoimmune disorders and malaria from 1 May 2020
Page last updated: 23 April 2020
Commencing 1 May 2020, the Pharmaceutical Benefits Scheme (PBS) listings for hydroxychloroquine will change.
The current general unrestricted benefits listing of hydroxychloroquine on the PBS is split into separate initial and continuing treatment listings for the TGA approved indications of malaria or autoimmune disorders. Both initial and continuing PBS listings will be Authority Required (STREAMLINED). Under the initial PBS listing, initial therapy must be authorised by a medical practitioner of any of the specialities defined in the clinical criteria.
